Regulated information

Availability of the 2023 universal registration document

On 24 April 2024, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format).

2023 ANNUAL RESULTS

Annual sales: €529m (stable at constant exchange rates)
Essentials sales: €313m (+4.5% at constant exchange rates)
Net income - Group share: €56m (10.5% of sales)
EBITDA: €113m (21.3% of sales)
Free cash-flow: €89m

Annual sales 2023: €529 million

Annual Sales of Essential products: €313 million (up 4.5% at constant exchange rates)

Sales 3rd quarter 2023: 136M€

The Vetoquinol Group posted sales of €136 million in Q3 2023, up +1.3% on a reported basis and +5.1% at constant exchange rates. Over the same period, Vetoquinol recorded a negative currency impact of -€5 million, linked to the Americas and Asia Pacific/Rest of World territories.

2023 HALF-YEAR RESULTS

Sales: €256m (-5.4% as reported)
Essentials products sales: €151m (59% of Group sales)
Net income - Group share: €32m (12.6% of sales)
EBITDA*: €54m (20.9% of sales)
Cash-flow generation: €31m

Q1 2023 Sales: €145M

Vetoquinol recorded sales of €145 million for the first three months of the 2023 financial year, up 7.7% on a reported basis and 7.2% at constant exchange rates.

Availability of the 2022 universal registration document

On 13 April 2023, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format).

Buyback programs – March 2023

Monthly communication regarding buyback programs

Clone of Buyback programs – April 2023

Monthly communication regarding buyback programs

Buyback programs – May 2023

Monthly communication regarding buyback programs

Buyback programs – June 2023

Monthly communication regarding buyback programs

2022 ANNUAL RESULTS

Annual sales: €540m (up 3.6% as reported)
Essentials sales: €304m (up 4.5% as reported)
EBIT before depreciation of acquired assets: €99m (18.3% of sales)
Net income - Group share: €48m (8.9% of sales)
EBITDA: €118m (21.9% of sales)
Free cash-flow: €63m

Annual sales 2022

Total group Sales: €540 million (up 3.6% as reported)
Annual Sales of Essential products: €304 million (up 4.5% as reported)

First nine months 2022 sales: €405M

In line with year-end outlook

2022 HALF YEAR RESULTS Additional information on the Group’s strategy

Following the conference call organised on 15 September 2022 to present its half-year results, Vetoquinol would like to provide some additional information on the strategy implemented and its outlook.

2022 HALF YEAR RESULTS

Sales: €271m (up 6.0% as reported)
Essentials sales: €154m (up 9.8% as reported)
EBIT before depreciation of acquired assets: €52m (19.0% of sales)
Net income - Group share: €21m (7.9% of sales)
EBITDA: €62m (22.9% of sales)

H1 2022 Sales

H1 2022 Sales: €271m, up 6.1%
+2.0% on a like-for-like basis
H1 2022 Essentials Sales: €154m, up 9.8%
+6.8% on a like-for-like basis

Buyback programs - may 2022

Monthly communication regarding buyback programs

Buyback programs - april 2022

Monthly communication regarding buyback programs

Availability of the 2021 universal registration document

Vetoquinol informs that it has filed its 2021 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 22th, 2022.

Q1 2022 SALES: €135M

Q1 2022 SALES: €135M
(UP 5.5% AS REPORTED, UP 2.2% AT CONSTANT EXCHANGE RATES)
Q1 2022 ESSENTIALS SALES: €77M
(UP 8.1% AS REPORTED, UP 5.5 AT CONSTANT EXCHANGE RATES)

Buyback programs - march 2022

Monthly communication regarding buyback programs

2021 Annual results

ALL FINANCIAL INDICATORS UP.
Annual sales: €521m (up 21.9% as reported).
Essentials sales: €296m (up 34.0% as reported).
EBIT before depreciation of acquired assets: €101m (up 54.5%).
Net income - Group share: €63m (up 226.9%).

Buyback programs - february 2022

Buyback programs - February 2022

Buyback programs - January 2022

Double-digit growth in 2021

Total Group Sales: €521 million (up 21.9% as reported)
Annual Sale of Essential products: €296 million (up 34.0% as reported)

Programme de rachat - Décembre 2021

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres.

Programme de rachat - November 2021

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

Programme de rachat - October 2021

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

Third quarter revenues: €132 million

Programme de rachat - September 2021

Programme de rachat - August 2021

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

Programme de rachat - July 2021

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

2021 first half results

2021 Half year results

Programme de rachat - May 2021

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

Programme de rachat - May 2021

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

Programme de rachat - April 2021

Availability of the 2020 universal registration document

Vetoquinol informs that it has filed its 2020 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 28th, 2021.

Q1 2021 sales

Programme de rachat - March 2021

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

2020 annual results 2020 sales: €427.5m (up 8.0% as reported)

Programme de rachat - February 2021

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

Vetoquinol wins the Animal Pharm’s award for best European company 2020

February 8th, 2021 (Lure, France) - Vetoquinol announced today it has been awarded “Best European Company 2020” by Animal Pharm.

Vetoquinol acquires the rights for Profender® from Elanco Animal Health for Canada

February 8th, 2021 (Lure, France) - Vetoquinol announced today the acquisition of the Canadian rights to Profender® product family from Elanco Animal Health.

Programme de rachat - January 2021

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

2020 sales: €427.5M (up 8.0% as reported, up 10.9% at constant exchange rate) essentials sales: €220.6M (up 15.7% as reported, up 17.3% at constant exchange rate)

Vetoquinol CEO Matthieu Frechin said: “2020 was an exceptional year on a number of counts. Above all, it is important to pay tribute to our teams, whose hard work and exemplary dedication allowed us to manage the impact of the health crisis. Year on year, we achieved double-digit sales growth at constant exchange rates, driven by our Essentials products. This momentum accounts for additional sales of €43 million (at constant exchange rates). We also completed a major acquisition in the form of the Drontal® and Profender® product ranges, entailing three structural effects for Vetoquinol: a scale effect, a product mix effect in the Essentials range and potential extensions, the first of which has been confirmed in January 2021 for the Australian market. We are optimistic for our business outlook in 2021, while being vigilant in relation to the global sanitary situation.”

Orion Animal Health and Vetoquinol expand collaboration - Vetoquinol to distribute Orion’s Clevor® in the USA and Orion to distribute Drontal® and Profender® products in Finland, Hungary and Romania

Orion Animal Health and Vetoquinol are expanding their collaboration with new distribution agreements.

Vetoquinol acquires the rights for Drontal® and Profender® families from Elanco animal health for Australia

January 11th, 2021 (Lure, France) - Vetoquinol announced today the acquisition of the Australian rights to Drontal® and Profender® product families from Elanco Animal Health.

Programme de rachat - December 2020

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

Programme de rachat - November 2020

Programme de rachat - October 2020

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

Q3 2020 sales: €114.5 million* (Up 14.3%)

Vetoquinol posted sales of €114.5 million for the third quarter of 2020, up 14.3% as reported compared to the same period last year.

Programme de rachat - September 2020

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

VETOQUINOL, SNGTV and FARMVETSYSTEMS sign a partnership agreement to offer a common, innovative digital solution to the veterinary healthcare market. September 28th, 2020 (Paris, France) VETOQUINOL, FARMVET SYSTEMS and SNGTV have signed a partnership agreement aimed at offering a common solution highlighting the complementarity of their two software, VetIMPRESS and Vetélevage to farm vets. Aware of their shared philosophy aimed at optimizing vets actions thanks to new digital technologies, they are pooling these two software programs to strengthen the role of farm vets in animal health and welfare.

Vetimpress delivering digital solutions to farm vets with a growing network of partnerships

September 21st, 2020 (Northern Ireland) – VetIMPRESS the secure data management platform has recently implemented a series of integrations, reinforcing its position as a leading source of information for farm animal vets. The platform has grown its connections to over 100 external sources across 10 countries. The partnerships are set to improve connectivity across the industry, providing a single source of truth to better inform ethical, safe and productive veterinary decisions.
 

Programme de rachat - August 2020

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

Vetoquinol finalizes the acquisition of Profender® and Drontal® product families

September 1st, 2020 (Lure, France) – Vetoquinol confirms the completion of the acquisition of Profender® and Drontal® product families for the European Economic Area and the UK. This acquisition is effective from August 1st, 2020.

Programme de rachat - July 2020

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

2020 first half results consolidated sales: €196.1m (up 7.5% at constant exchange rates) net income group share: €15.1m (7.7% of sales)

At its meeting on July 29, 2020, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the first half 2020 financial statements. The auditors have completed their audit of the financial statements and will shortly issue their report thereon.

Programme de rachat - June 2020

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

Vetoquinol is moving forward with the acquisition of Profender® and Drontal® and related pipeline assets following communication from the European commission

June 9th, 2020 (Lure, France) - The European Commission (EC) has approved, under the EU merger Regulation, the proposed acquisition of Bayer’s Animal Health Division by Elanco Animal Health.

Programme de rachat - May 2020

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

Programme de rachat - April 2020

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

Dominique Derveaux appointed Group Chief Operations Officer Effective April 1, 2020, Vetoquinol’s Board of Directors has appointed Dominique Derveaux Group Chief Operations Officer. In this capacity, he will run the Business, Marketing & Medical, Industrial, and Information Systems departments. He will report to Vetoquinol CEO Matthieu Frechin.

Availability of the 2019 universal registration document

Vetoquinol informs that it has filed its 2019 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 23, 2020.

Q1 2020 sales €103.4 million (Up 13.7%)

Vetoquinol Group sales for Q1 2020 amounted to €103.4 million, up 13.7% as reported and up 13.4% at constant exchange rates.

Programme de rachat - March 2020

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

Information hebdomadaire relative aux transactions réalisées sur ses propres titres (30 mars 2020)

Conformément aux dispositions de l’article 241-4 du Règlement Général de l’Autorité des Marchés Financiers 

2019 annual results: group sales €396.0M, up 6.1% at constant exchange rates. Net income group share: €28.6M (7.2% of sales)

At its meeting on March 24, 2020, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the 2019 financial statements. The auditors have completed their audit of the financial statements and will shortly issue their report thereon.

Information hebdomadaire relative aux transactions réalisées sur ses propres titres (23 mars 2020)

Conformément aux dispositions de l’article 241-4 du Règlement Général de l’Autorité des Marchés Financiers 

Covid-19: Vetoquinol donates masks to neighboring healthcare facilities

Vetoquinol S.A, the animal health laboratory based in Lure (70) has decided to donate more than 6000 masks to hospitals and associations in the region. This is a civic action to help, amongst others, hospitals in the Belfort Montbéliard, Vesoul and Saint-Rémy regions.

Programme de rachat - February 2020

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

Vetoquinol to acquire rights for Profender® and Drontal® from Elanco Animal Health for the European economic area and the UK

February 12 th , 2020 (Lure, France) - Vetoquinol has agreed terms to acquire the European Economic area and UK rights to Profender® and Drontal® product families from Elanco Animal Health.

Programme de rachat - January 2020

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

2019 sales: €396.0 million (Up 7.6%)

The Vetoquinol Group posted 2019 sales of €396.0 million, up 7.6% as reported and up 6.1% at constant exchange rates.

Programme de rachat - December 2019 (french)

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

Vetoquinol and Klox Technologies Announce Global Animal Health Collaboration Agreement

December 12, 2019 (Lure, France) - Vetoquinol S.A. and Klox Technologies Limited, a subsidiary of Klox Technologies Inc., have entered into an exclusive global licensing agreement, excluding the People’s Republic of China.

Programme de rachat - November 2019 (french)

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

Programme de rachat - October 2019 (french)

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

Q3 2019 sales: €100.2 million (Up 11.0%)

The Vetoquinol Group posted sales of €100.2 million for the third quarter of 2019, up 11.0% as reported and up 9.4% at constant exchange rates compared to the same period last year.

Programme de rachat - September 2019 (french)

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

Programme de rachat - Augsut 2019 (french)

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

Programme de rachat - July 2019(french)

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

First half 2019 results

At its meeting on July 24, 2019, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited first half 2019 financial statements.

Vetoquinol announces a new milestone in its industrial strategy

Vetoquinol, a leading global animal health player, today announces a plan to reorganize its production facilities in Europe. This decision is in line with the Group’s strategy of streamlining operations in order to improve its response to customer needs, whether vets, breeders or pet owners.

Combined ordinary and extraordinary general meeting May 21, 2019

The Combined Ordinary and Extraordinary General Meeting of Vetoquinol shareholders was held on Tuesday May 21, 2019 in Lure, chaired by Etienne Frechin.

Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2018 (french version)

Information hebdomadaire relative aux transactions réalisées sur ses propres titres (26 avril 2019)

Conformément aux dispositions de l’article 241-4 du Règlement Général de l’Autorité des Marchés Financiers 

Q1 2019 sales: €90.9 million (up 3.7%)

Vetoquinol Group sales for Q1 2019 amounted to €90.9 million, up 2.3% at constant exchange rates and up 3.7% as reportedfrom the same period last year.

Vetoquinol finalizes acquisition of Clarion Biociencias in Brazil

Lure (France), April 16, 2019 - Vetoquinol today confirms the completion of its acquisition of Clarion Biociências, a Brazilian veterinary laboratory based in the state of Goiás.

Vetoquinol signs agreement to acquire Clarion Biociênciasin Brazil

On April 3rd, Vetoquinol signed an agreement to acquire Clarion Biociências, a Brazilian veterinary laboratory based in the state of Goiás.

Growth in all financial indicators in 2018. Essentials products sales: €179.4M (up 9.1% at constant exchange rates). Net income group share €36.3M (up 4.0%)

At its meeting on March 19, 2019, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited 2018 financial statements.

Programme de rachat - January 2019 (french)

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

2018 sales: up 3.2% to €367.9 million

9.1% GROWTH IN ESSENTIALS PRODUCTS AT CONSTANT EXCHANGE RATES

Information hebdomadaire relative aux transactions réalisées sur ses propres titres (20 au 24 juin 2016)

Conformément aux dispositions de l’article 241-4 du Règlement Général de l’Autorité des Marchés Financiers 

Programme de rachat - November 2017 (french)

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

Information hebdomadaire relative aux transactions réalisées sur ses propres titres (20 au 24 juin 2016)

Conformément aux dispositions de l’article 241-4 du Règlement Général de l’Autorité des Marchés Financiers 

Information hebdomadaire relative aux transactions réalisées sur ses propres titres (20 au 24 juin 2016)

Conformément aux dispositions de l’article 241-4 du Règlement Général de l’Autorité des Marchés Financiers 

Programme de rachat - November 2017 (french)

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

Information hebdomadaire relative aux transactions réalisées sur ses propres titres (20 au 24 juin 2016)

Conformément aux dispositions de l’article 241-4 du Règlement Général de l’Autorité des Marchés Financiers